Mumbai, India–headquartered Lupin Pharmaceuticals (NYSE:LUPIN) has received an expanded indication for Solosec (secnidazole) to cover the treatment of trichomoniasis in adult patients and their partners.  The drug scored an initial FDA approval in 2017 for bacterial vaginosis (BV) in adult women.  Solosec is now the only single-dose oral drug that has an FDA indication for both…